DANBURY, Conn., July 29 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the Company will present at the Wedbush Securities Life Sciences Best Ideas Management Access Conference on Tuesday, August 3rd. Dr. Errol De Souza, President and Chief Executive Officer will make a presentation on the company at 11:10 a.m. Eastern time (8:10 a.m. Pacific time) at the Le Parker Meridien Hotel in New York. The Wedbush Life Sciences Conference provides participating companies with the opportunity to present to institutional and private equity investors.
A live audio webcast of the presentation will be available by visiting Biodel’s website at www.biodel.com. An archive of the presentation at the Wedbush Life Sciences Conference will be available on the Biodel’s website for 30 days.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel’s product candidates are developed using VIAdel technology, which reformulates existing FDA-approved peptide drugs. Biodel’s new drug application for its most advanced product candidate, VIAject®, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company’s website at www.biodel.com.
Contact: | |
Seth Lewis | |
The Trout Group, LLC | |
+1-646-378-2952 | |
BIOD-G
SOURCE Biodel Inc.
